Recombinant Allergens in Diagnosis and Therapy of Allergic Diseases (original) (raw)
The component-resolved diagnosis use in routine clinical and laboratory practice has increased in recent years. Recombinant allergens can be produced with high purity by using controlled procedures, obtaining molecules with known molecular, immunologic, and biological characteristics; they can help clinicians to treat patients with multiple pollen sensitisations. Recombinant allergens are useful in respiratory allergies such as: grass pollen, birch pollen, parietaria pollen, olive pollen, and dermatophagoides in food allergies, especially milk, eggs and peanuts. Recombinant allergens constitute an important tool in diagnosis and therapy of allergic diseases, which allows a better characterisation of the allergic patient.
Related papers
Recombinant allergens for pollen immunotherapy
Immunotherapy, 2013
Specific immunotherapy (IT) represents the only potentially curative therapeutic intervention of allergic diseases capable of suppressing allergy-associated symptoms not only during treatment, but also after its cessation. Presently, IT is performed with allergen extracts, which represent a heterogeneous mixture of allergenic, as well as nonallergenic, compounds of a given allergen source. To overcome many of the problems associated with extract-based IT, strategies based on the use of recombinant allergens or derivatives thereof have been developed. This review focuses on recombinant technologies to produce allergy therapeuticals, especially for allergies caused by tree, grass and weed pollen, as they are among the most prevalent allergic disorders affecting the population of industrialized societies. The reduction of IgE-binding of recombinant allergen derivatives appears to be mandatory to increase the safety profile of vaccine candidates. Moreover, increased immunogenicity is ex...
Journal of Allergy and Clinical Immunology, 1997
Background: Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in vitro and in vivo. Objective: The study was carried out to determine whether the potency of recombinant Bet v 1 (rBet v 1) is comparable to that of natural Bet v 1 (nBet v 1) in inducing allergic reactions in the nose and bronchi. Methods: Thirteen patients allergic to birch pollen with bronchial asthma and/or rhinitis were investigated. Skin prick tests and nasal and bronchial challenges were performed with rBet v 1 and nBet v 1.
Recombinant Allergens: A Significant Tool of Immunotherapy
The broad applicability of allergen-specific immunotherapy for the treatment and eventual prevention of Ig E - mediated allergy is limited by the poor quality and allergenic activity of natural allergen extracts that are used for the production of current allergy vaccines. Recombinant allergens equalling their natural counterparts have been produced for diagnosis and immunotherapy, and a large panel of genetically modified allergens with reduced allergenic activity has been characterized to improve safety of immunotherapy and explore allergen-specific prevention strategies. Recombinant allergens can be produced as defined molecules with consistent quality and unlimited amounts according to the corresponding DNA template. The recombinant allergen-based vaccination strategies will be generally applicable to most allergen sources, including respiratory, food and venom allergens and allow producing safe allergy vaccines for the treatment of the most common forms of IgE-mediated allergies.
Molecular Approach to Allergy Diagnosis and Therapy
Yonsei Medical Journal, 2014
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recombinant allergens in specific immunotherapy
Allergo Journal International, 2015
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. The editors gratefully thank Thermo Fisher Scientific, Phadia AB, Uppsala, Sweden, for the educational grant provided supporting English translation and language revision. Based partially on the German language edition: Molekulare Allergiediagnostik by Jörg Kleine-Tebbe, Thilo Jakob.
Recombinant allergens for immunoblot diagnosis of tree-pollen allergy
Journal of Allergy and Clinical Immunology, 1991
Diagnosis of type I allergy essentially depends on the availability of dejTned allergens, which can be provided by recombinant deoxyribonucleic acid (DNA) technology. We have previously isolated the c(complementary)DNAs encoding the major birch-pollen allergen, Bet v I, and another allergen with a molecular weight of 14 kd that was identiJied as birch proflin and designated Bet v II. These cDNAs were isolated from a lambda gtll expression library by screening with the serum IgE from allergic patients. To obtain expression in Escherichia coli of recombinant allergens without additional fused polypeptides, both cDNAs were inserted into the plasmid pKK223-3. E. coli cells expressing Bet v I and birch proj'ilin (Bet v II) were used for the preparation of recombinant proteins. These proteins were tested for their IgE-binding properties on immunoblots with sera from 100 difSerent birch pollen-allergic patients. All patients' sera, which reacted with the natural allergens, Bet v I and Bet v II, demonstrated an identical IgE-binding pattern to recombinant birch-pollen allergens. Recombinant allergens may therefore be useful for the setup of diagnostic tests that allow the discrimination of difSerent IgE-binding patterns as well as for patient-tailored immunotherapy. (J ALLERGY CLIN IMMIJNOL 1991;88:889-94.)
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.